Shaorong Li

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

B. Shao, Huiping Li, Z. Tong, 2022, BMC Medicine.

Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers

Ting Li, Yan-ping Liu, Shu-qin Liu, 2022, Drugs in R&D.

Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants

Hengli Zhao, Qing Wen, Shaorong Li, 2023, Clinical pharmacology in drug development.

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

D. Zhong, Yi-cong Bian, Yan Zhan, 2023, Frontiers in Pharmacology.

Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study

J. Wang, W. Fang, Yun-peng Yang, 2023, Cancer Chemotherapy and Pharmacology.

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study

R. Liu, Y. Ba, T. Deng, 2023, Therapeutic advances in medical oncology.